Clinical features of long-term survivors with advanced high-grade serous ovarian cancer.

被引：0
|
作者：
Barretina-Ginesta, Maria-Pilar
Bague, Anna Carbo
Bujons, Elisabet
Fortian, Arola
Fina, Claudia
Pardo, Marta
Melendez-Munoz, Cristina
Cardenas, Laura
Taltavull, Anna
Sabate, Josep
Darder, Esther
Feliubadalo, Lidia
Barretina, Jordi
Brunet, Joan
机构：
[1] Catalan Inst Oncol, Med Oncol, Girona, Spain
[2] Univ Girona, Girona Biomed Res Inst, Sch Med, Girona, Spain
[3] Catalan Inst Oncol, Dept Med Oncol, Girona, Spain
[4] Hosp Univ Dr Josep Trueta, Girona, Spain
[5] Inst Recerca Germans Trias & Pujol, Badalona, Spain
[6] Inst Invest Biomed Girona, Girona, Spain
[7] Hosp Univ Dr Josep Trueta, Dept Pathol, Girona, Spain
[8] Hosp Univ Dr Josep Trueta, Dept Gynecol, Girona, Spain
[9] IDIBGI, Hereditary Canc Program, Catalan Inst Oncol, Girona, Spain
[10] IDIBELL, Hereditary Canc Program, Catalan Inst Oncol, Lhospitalet De Llobregat, Spain
[11] Girona Biomed Res Inst IDIBGi, Girona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17575
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Drug resistance in end-stage high-grade serous ovarian cancer.
    Christie, Elizabeth L.
    Alsop, Kathryn
    Au-Yeung, George
    Pandey, Ahwan
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 17 - 17
  • [32] PAX8-directed nanotherapeutics for high-grade serous ovarian cancer.
    Chandrasekaran, Akshaya
    Ahmed, Mariam
    Holub, Nicole
    Wang, Wade
    Hammond, Paula T.
    Elias, Kevin M.
    CANCER RESEARCH, 2021, 81 (13)
  • [33] Singling out tumor heterogeneity and chemoresistance in high-grade serous ovarian cancer.
    Erkan, Erdogan Pekcan
    Dai, Jun
    Zhang, Kaiyang
    Kaipio, Katja
    Lamminen, Tarja
    Mansuri, Naziha
    Suominen, Lasse
    Alkodsi, Amjad
    Huhtinen, Kaisa
    Hietanen, Sakari
    Hynninen, Johanna
    Grenman, Seija
    Carpen, Olli
    Hautaniemi, Sampsa
    Vaharautio, Anna
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 59 - 59
  • [34] Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
    Lana E. Kandalaft
    Denarda Dangaj Laniti
    George Coukos
    Nature Reviews Cancer, 2022, 22 : 640 - 656
  • [35] Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
    Kandalaft, Lana E.
    Laniti, Denarda Dangaj
    Coukos, George
    NATURE REVIEWS CANCER, 2022, 22 (11) : 640 - 656
  • [36] Characterization of primary-metastasis pairs in high-grade serous ovarian cancer with short- and long-term survival
    Kotnik, E. N.
    Spies, N.
    Miller, C. A.
    Li, T.
    Inkman, M.
    Zhang, J.
    Guo, L.
    Maher, C.
    McCourt, C. K.
    Thaker, P. H.
    Hagemann, A. R.
    Mutch, D. G.
    Powell, M. A.
    Fuh, K. C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 264 - 264
  • [37] First-Line Management of Advanced High-Grade Serous Ovarian Cancer
    Mahmood, Reem D.
    Morgan, Robert D.
    Edmondson, Richard J.
    Clamp, Andrew R.
    Jayson, Gordon C.
    CURRENT ONCOLOGY REPORTS, 2020, 22 (06)
  • [38] First-Line Management of Advanced High-Grade Serous Ovarian Cancer
    Reem D. Mahmood
    Robert D. Morgan
    Richard J. Edmondson
    Andrew R. Clamp
    Gordon C. Jayson
    Current Oncology Reports, 2020, 22
  • [39] Gonadotropin receptors as targetable biomarkers in advanced, high-grade serous ovarian cancer
    Mallen, A. R.
    Han, M.
    Park, H.
    Henry, B.
    Boac, B. M.
    Wenham, R. M.
    Conejo-Garcia, J.
    Xiong, Y.
    Marchion, D. C.
    Magliocco, A.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 244 - 245
  • [40] Variance of HRD score from primary to recurrent in high-grade serous ovarian cancer.
    Chen, Xiaoxiang
    Ni, Jing
    Xu, Xia
    Guo, Wenwen
    Zhao, Qian
    Cheng, Xianzhong
    Zhou, Rui
    Gu, Hongyuan
    Chen, Chen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345